Mehabe score: 3 G Factor: 4 Piotski Score: 8 The stock has a rating . The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 4 and Piotski score of 8.
Description
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.Site:MARKSANSMain Symbol:MARKSANS
Stock trades at 67.4, below its 50dma 73.22 and below its 200dma 67.97. The stock remains bearish on technicals
The 52 week high is at 97.60 and the 52week low is at 48.00
Price Chart
P/E Chart
Sales and Margin
Strengths
– is almost debt free.
– has delivered good profit growth of 24.76% CAGR over last 5 years
Weakness
– The company has delivered a poor sales growth of 9.03% over past five years.
Competition
– The industry trades at a mean P/E of 21.7x. Divi’s Lab. trades at the industry’s max P/E of 61.53x. MARKSANS trades at a P/E of 11.0x
– Industry’s mean G-Factor is 3.2 while the mean Piotski score is 8.0. MARKSANS has a G-Factor of 4 and Piotski scoreof 8.
– Average 1 month return for industry is -3.5%. The max 1- month return was given by Hikal: a return of 0.88 %
Quarterly Results
Sales for period ended Jun 2021 is Rs 349.0 cr compared to Rs 331.0 cr for period ended Jun 2020, a rise of 5.4%
Operating Profits reported at Rs 77.0 cr for period ended Jun 2021 vis-vis 70.0 for period ended Jun 2020 .
Operating Margins expanded 91.5 bps for period ended Jun 2021 vis-vis Jun 2020 .
The EPS for Jun 2021 was Rs 1.53 compared to Rs 1.94 for previous quarter ended Mar 2021 and Rs 1.21 for Jun 2020
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 1394.0 cr for period ended TTM vis-vis sales of Rs 1376.0 cr for the period ended Mar 2021, a growth of 1.3%. The 3 year sales cagr stood at 11.7%.
Net Profit reported at Rs 252.0 cr for period ended TTM vis-vis sales of Rs 239.0 cr for the period ended Mar 2021, rising 5.2%.
Company recorded a healthy Net Profit CAGR of 49.1% over the last 3 years
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
CashFlow from operating activities was positive.
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has improved its Return on Equity (RoE) metric. The RoE on Last Year basis was 31.0% compared to 23.0% over the last 3 Years. – The stock has given a return of 37% on a 1 Year basis vis-vis a return of 25% over the last 3 Years. – The compounded sales growth on a TTM bassis is 15% vis-vis a compounded sales growth of 15% over the last 3 Years. – The compounded profit growth on a TTM basis is 71% vis-vis a compounded profit growth of 93% over the last 3 Years.
Ratios
Shareholding Pattern
– FII shareholding has remained largely constant. The Sep 2021 fii holding stood at 2.64% vis-vis 3.14% for Jun 2021 – Public shareholding has remained largely constant. The Sep 2021 public holding stood at 48.58% vis-vis 48.05% for Jun 2021
Conclusion
– is almost debt free.
– has delivered good profit growth of 24.76% CAGR over last 5 years – The company has delivered a poor sales growth of 9.03% over past five years.
